Artemisinin partial resistance may facilitate selection of Plasmodium falciparum resistant to
combination therapy partner drugs. We evaluated 99 P. falciparum isolates collected in 2021 …

Febrile illness is a major burden in African children, and non-malarial causes of fever are
uncertain. In this retrospective exploratory study, we used metagenomic next-generation …

Background Treatment and control of malaria depends on artemisinin-based combination
therapies (ACTs) and is challenged by drug resistance, but thus far resistance to artemisinins …

Dihydroartemisinin-piperaquine (DP) has demonstrated excellent efficacy for the treatment
and prevention of malaria in Uganda. However, resistance to both components of this …

Changing treatment practices may be selecting for changes in the drug sensitivity of malaria
parasites. We characterized ex vivo drug sensitivity and parasite polymorphisms associated …

The proteasome is a promising target for antimalarial chemotherapy. We assessed ex vivo
susceptibilities of fresh Plasmodium falciparum isolates from eastern Uganda to seven …

In many malaria‐endemic regions, current detection tools are inadequate in diagnostic
accuracy and accessibility. To meet the need for direct, phenotypic, and automated malaria …

Background The Plasmodium falciparum dihydrofolate reductase (PfDHFR) inhibitors
pyrimethamine and cycloguanil (the active metabolite of proguanil) have important roles in malaria …

Malaria, especially Plasmodium falciparum infection, remains an enormous problem, and its
treatment and control are seriously challenged by drug resistance. New antimalarial drugs …

Polymorphisms in the Plasmodium falciparum multidrug resistance 1 (pfmdr1) gene impact
sensitivity to multiple antimalarials. In Africa, polymorphisms at N86Y and D1246Y are …